CombinatoRx scores $40M payout on FDA approval

CombinatoRx's complex merger deal with Neuromed will pay off with a $40 million milestone earned with today's announcement that the FDA has approved Exalgo, a once-daily pain therapy. Covidien, which partnered on the program, will handle the commercial rollout and fork over the cash.

Read the full article at FierceBiotech

Share this Post:
Digg Google Bookmarks reddit Mixx StumbleUpon Technorati Yahoo! Buzz DesignFloat Delicious BlinkList Furl

No Responses to “CombinatoRx scores $40M payout on FDA approval”

Leave a Reply:

Name (required):
Mail (will not be published) (required):
Website:
Comment (required):
XHTML: You can use these tags: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <strike> <strong>

Get Adobe Flash playerPlugin by wpburn.com wordpress themes